Rapid reduction in BCR ‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

ConclusionsPrimary treatment of CML‐CP with dasatinib enabled early achievement of MMR and DMR, particularly in elderly patients, with high safety. Furthermore, RR‐BCR‐ABL13m was found to be a more useful predictor of DMR than HT‐BCR‐ABL1 and BCR‐ABL1 IS.

Source: European Journal of Haematology - October 16, 2017 Category: Hematology Authors: Kazunori Murai, Kohei Yamaguchi, Shigeki Ito, Takuto Miyagishima, Motohiro Shindo, Kentaro Wakasa, Mitsue Inomata, Takahiro Nagashima, Takeshi Kondo, Nozomu Fujimoto, Satoshi Yamamoto, Masakatsu Yonezumi, Tatsuo Oyake, Shugo Kowata, Yasuhiko Tsukushi, Tak Tags: ORIGINAL ARTICLE Source Type: research